Alpa Mirella Torino 13° Convegno Patologia Immune E Malattie Orfane 21 23 Gennaio 2010 [Modalità Compati

•

0 likes•333 views

This document summarizes the experience of using the monoclonal antibody rituximab to treat 11 patients with various forms of vasculitis at a single medical center in Italy. All patients had active organ involvement and were failing standard therapies. Patients received rituximab treatment and were found to have significantly reduced disease activity and organ involvement after 12 months as measured by the Birmingham Vasculitis Activity Score and Vasculitis Damage Index. This case series provides evidence that rituximab may be effective for treating refractory vasculitis when other treatments have failed.

Health & Medicine

13° CONVEGNOPATOLOGIA IMMUNE E
13°CONVEGNO PATOLOGIA IMMUNE E
MALATTIE ORFANE, Torino 21-23/01/10
21-

FARMACI BIOLOGICI NELLE VASCULITI
ESPERIENZA MONOCENTRICA CMID

MIRELLA ALPA

Dipartimento di Malattie Rare, Immunologiche, Ematologiche ed Immunoematologiche
Centro di Ricerche di Immunopatologia e Documentazione su Malattie Rare (CMID)
Struttura Complessa a Direzione Universitaria di Immunologia Clinica, Ospedale G. Bosco

CLINICAL FEATURES AND OUTCOME OF PSV PTS TREATED WITH ANTICD20 MoAb
PATIENT, ACTIVE ORGAN URINARY HEMATURIA
FAILING THERAPY CREATININE VAS SCALE DIAGNOSIS
AGE/GENDER INVOLVEMENT PROTEINS
1/39/M MMF, MTX, SP, K, PNS, J , F, S, W 0.7 0.4 50 9 mPa
IVIgG, PE
C
2/67/F MMF, SP K, F, W 1.1 1.1 50 7 mPa
I
3/63/M Oral CYC, SP K, J, W 2.4 1.3 40 7 mPa
R
4/71/F Oral CYC, SP PNS, J, F 0.9 0.5 0 6 mPa
R
5/69/M MMF, SP K, PNS, J, F, W 1.4 1.4 15 6 WG
relapsing

6/62/F MMF, K, L, F,W, PNS, J, 2.1 2.2 20 9 WG
I SP, IVIgG M, ent
7/60/M CYC, PNS, S, J, H ,W 1.2 0.3 0 9 CS
R SP, IVIgG

8/35/M Steroid L, F, W, J, ent 0.9 0.1 0 8 CS
C
9/50/M Steroid, Mtx, anti- PNS, W, J, ent 0.8 0.1 5 7 WG
TNF
R
10/49/F SP, CYC, AZA, CyA K, W, J, PNS, ent 1.1 3.4 5 8 WG
R
11/68/F SP, Oral CYC, IVIgG, K, ent, CNS, L 2 0.9 10 9 WG
PE
R

PATIENTS AND PROTOCOL

11 PTS: 5 WOMEN, 6 MEN (5 WG, 4 MPA, 2 CS)
PTS: WG, MPA, CS)
WITH INVOLVEMENT OF
KIDNEY #7
PNS #7
ENT #5
LUNG #3
RETROORBITAL OR SINUS GRANULOMATA #2
CNS #1

RITUXIMAB 375 mg/sm DAYS # 0, 7, 14, 21 plus 2 DOSES AT 1 AND 2
MTHS

35

30 29

28

26 B-VAS
25

20
20

15 16
15

12
11
10

6
5

3
2
2

0
T0 T12

p<0.01 at 12 months

20

18 18

16

14
13 VDI
12

10
9
8 8
7
6 6 6

4 4
4
3
2 2
1
0 0 0
T0 T12

p<0.01 at 12 months

This document discusses advances in gastrointestinal stromal tumors (GIST), including: 1. Common mutations found in KIT (CD117) receptor tyrosine kinase that are associated with GIST and their sensitivity to tyrosine kinase inhibitors (TKIs). 2. Treatment algorithms for patients with resectable or unresectable/metastatic GIST based on mutational profiling. 3. Studies of various TKIs for imatinib-resistant GIST as well as novel agents targeting mTOR and HSP90 pathways for refractory disease.

Icncaoccn 2012 poster shiihara t

Takashi Shiihara

This study measured biomarkers (S100B, NSE, tau protein) in the serum and cerebrospinal fluid of patients with either febrile seizures or acute encephalopathy with biphasic seizures and late reduced diffusion. Biomarker levels were significantly higher in acute encephalopathy patients, even early in the illness. CSF levels of S100B and tau protein best distinguished acute encephalopathy from febrile seizures and could help with early diagnosis. Combining CSF S100B and tau levels achieved good sensitivity and specificity for identifying acute encephalopathy. The results suggest acute encephalopathy is associated with damage to astrocytes, neurons and axons from the early stages.

Hépatite C_Résistance aux traitements.ppt

odeckmyn

The document discusses hepatitis C virus (HCV) resistance to different antiviral treatments. It finds that HCV resistance to interferon-alpha therapy exists but accounts for only a small portion of treatment failures. Resistance to ribavirin is unclear as its mechanism of action is not fully understood. Direct acting antivirals in development target various stages of the HCV life cycle and resistance can emerge through amino acid substitutions, but combination therapy aims to prevent resistance.

DIAGNOSTIC PERFORMANCE OF FOOT-AND-MOUTH DISEASE VIRUS DETECTION AND SEROTYPI...

EuFMD

This study evaluated different diagnostic assays for detecting and typing foot-and-mouth disease virus (FMDV) in field samples from northern Tanzania between 2012-2018. Topotype-specific real-time RT-PCR assays correctly identified the specific FMDV types circulating in East Africa with high accuracy, detecting types O, A, SAT1 and SAT2. Antigen-ELISA kits had lower sensitivity but provided easy serotyping. Using the assays together achieved nearly 100% diagnostic sensitivity and typing performance. A total of 127 samples were tested, with 119 identified as one of the four FMDV types and six negative for FMDV but positive for Bovine Viral Diarrhea Virus in three cases.

ARM 2007: Dissection, characterisation and utilisation of disease QTL -- R Ne...

CGIAR Generation Challenge Programme

1. The document discusses several projects aimed at dissecting and utilizing quantitative trait loci (QTL) that confer disease resistance in rice and maize. 2. Multiple strategies are being used across different research groups, including linkage mapping, association mapping, analysis of near-isogenic lines and mutants, to map QTL and isolate the underlying genes. 3. Preliminary results from some projects show correlations between increased expression of germin-like protein genes and enhanced disease resistance in rice, as well as identification of QTL associated with resistance to different diseases like blast and drought tolerance.

Experimental challenge study of ranavirus infection in previously infected ea...

mgray11

This study examined whether eastern box turtles that survived a previous Ranavirus outbreak developed immunity. Eleven turtles were tested, with 7 inoculated with Ranavirus and 4 controls. 4 of the 7 inoculated turtles showed clinical signs. Only 1 inoculated turtle died. All inoculated turtles tested positive for Ranavirus in blood or oral swabs at some point. The results indicate eastern box turtles can be reinfected with Ranavirus after surviving an initial outbreak but many can survive reinfection, and reinfected turtles may still shed virus.

2009 Convegno Malattie Rare Marozio [24 01]

cmid

Morsolini Marco Torino 13° Convegno Patologia Immune E Malattie Orfane 21 23 ...

cmid

This document discusses pulmonary endarterectomy (PEA), a surgical procedure for chronic thromboembolic pulmonary hypertension (CTEPH). It provides an overview of: - CTEPH, its epidemiology, natural history, and indications for PEA based on clinical status, hemodynamics, and anatomy. - The Pavia PEA program's experience since 1994, including referral patterns, annual patient volumes increasing to over 50 cases per year, and evaluation/follow-up processes showing high operability rates. - Key findings from the program's studies of coagulation/immunologic disorders and genetic mutations common in CTEPH patients.

This document discusses various types of biomarkers for spinal muscular atrophy (SMA), including their definitions, examples, and validity. It provides details on prognostic biomarkers like SMN2 copy number, disease progression biomarkers like compound muscle action potential amplitude, predictive biomarkers for response to therapy, pharmacodynamic biomarkers that monitor therapeutic effects, and surrogate endpoints. The document also summarizes data on biomarker studies in SMA mice and human patients. Longitudinal changes in biomarkers like osteopontin, dipeptidyl peptidase IV, and tetranectin in SMA mice treated with antisense oligonucleotides are described.

Dr. Goy MCL

John Theurer Cancer Center at Hackensack University Medical Center

The document discusses the use of bortezomib, a proteasome inhibitor, for the treatment of mantle cell lymphoma (MCL). It summarizes several clinical trials that have shown bortezomib to be effective against MCL both as a single agent and in combination with chemotherapy regimens like R-CHOP. Ongoing studies are further exploring bortezomib combinations and schedules to improve outcomes for MCL patients.

Kappos fingolimod moa-clin_results_vfinal_buenosaires1a

rubenroa

1) Fingolimod is a sphingosine 1-phosphate receptor modulator approved for relapsing forms of multiple sclerosis. It works by retaining lymphocytes in lymph nodes, reducing their migration into the central nervous system. 2) Phase II clinical trial results showed fingolimod significantly reduced relapse rates and brain lesion activity compared to placebo over 5 years of follow up. It selectively retained naive and central memory T cells while sparing effector memory T cells. 3) Phase III FREEDOMS trial of over 1200 patients found fingolimod 0.5mg reduced annualized relapse rates by 54% and risk of disability progression by 30% compared to placebo over 2 years. It established

Martin duddy, drugs on the horizon

MS Trust

This document discusses new and emerging drugs for progressive multiple sclerosis. It provides an overview of the current treatment landscape and explores potential reasons for past clinical trial failures. It also examines the underlying pathological mechanisms of progressive disease and proposes that trials may have targeted the wrong outcomes, patient populations, or stages of disease progression. Ongoing trials of drugs like ocrelizumab and natalizumab aim to address some of these challenges by exploring therapies in earlier progressive phases and assessing disability outcomes over longer periods of time.

Estado actual de terapia sistémica en cáncer renal metastásico

Mauricio Lema

This document discusses the current management of metastatic renal cell carcinoma (mRCC). It provides an overview of targeted therapies for mRCC including tyrosine kinase inhibitors (TKIs) such as sunitinib, pazopanib, and cabozantinib that target the VEGF pathway. Clinical trial results are presented comparing TKIs in first-line mRCC. Active surveillance is also discussed as a treatment option for select asymptomatic or minimally symptomatic mRCC patients. Toxicities of TKIs like fatigue, diarrhea and hand-foot syndrome are reviewed along with their negative impact on quality of life.

Salvage Chemotherapy for Head and Neck Cancer 2021-07 (New).ppt

SuYuChieh1

Incyte INCB39110 study results

innovaderm

This document summarizes a Phase 2 clinical trial exploring the safety, tolerability, and efficacy of escalating doses of INCB039110, an oral JAK1 inhibitor, in subjects with chronic plaque psoriasis over 28 days. The trial found that INCB039110 produced statistically significant improvements in psoriasis severity compared to placebo based on measures like the static Physician's Global Assessment and PASI 50 response. Treatment was generally well tolerated with no evidence of myelosuppression. Decreases in platelets and increases in LDL and HDL were observed but remained within normal limits. The results demonstrate the potential for JAK1 inhibition as an effective oral treatment for psoriasis.

$MCO 2011 - Slide 4 - K. Fizazi - Castration-refractory prostate cancer$ $MCO 2011 - Slide 4 - K. Fizazi - Castration-refractory prostate cancer$

MCO 2011 - Slide 4 - K. Fizazi - Castration-refractory prostate cancer

European School of Oncology

1) Castrate-resistant prostate cancer (CRPC) has become increasingly treatable over the past decade with the approval of several new drugs including docetaxel, sipuleucel-T, cabazitaxel, denosumab, and abiraterone. 2) Clinical trials have shown that docetaxel improves survival when used to treat metastatic CRPC and cabazitaxel improves survival in CRPC progressing after docetaxel. 3) Denosumab has been shown to delay skeletal-related events in men with bone metastases from prostate cancer compared to zoledronic acid. Abiraterone has also improved survival in CRPC progressing after chemotherapy.

Cáncer páncreas 2017

UACH, Valdivia

- The document discusses pancreatic cancer epidemiology and molecular biology. Some key points: - Worldwide, pancreatic cancer incidence is about 8 per 100,000 and mortality is 7-8 per 100,000, making it the 8th most common cancer. - In Chile, incidence and mortality are slightly higher than worldwide averages. - About 60% of pancreatic cancers are metastatic at diagnosis, 30% are locally advanced, and only 10% are early-stage. - KRAS mutations are present in approximately 95% of pancreatic cancers.

Dr Alessandro Perra , Guna S,p.a.Italy

Investnet

This document summarizes a presentation on low dose cytokines in supportive cancer therapy. It discusses how low dose cytokines from GUNA S.p.a, such as IL-4, IL-12, and IFN-γ at concentrations of 10 fg/ml, can enhance the antigen presentation and stimulatory activity of dendritic cells obtained from early stage colorectal cancer patients. An ex vivo study found that sequential exposure of these patient's dendritic cells to low doses of IL-4 and IL-12 increased their ability to stimulate T-cell responses compared to treatment with standard doses of cytokines. The presentation concludes that GUNA's approach using low dose cytokines may provide a novel integrated therapy to activate the immune system in cancer.

Nets 2008 Carlos F Pinto

Carlos Frederico Pinto

This document summarizes recent advances in the treatment of neuroendocrine tumors. Several new agents have shown promising results in phase II trials, including pasireotide for tumors resistant to octreotide, everolimus combined with octreotide, sorafenib, sunitinib, and temsirolimus. These agents have multiple mechanisms of action and have led to partial responses and prolonged progression-free survival in early studies. While significant progress has been made, treatment of neuroendocrine tumors remains a work in progress as several phase III trials are currently evaluating mTOR and tyrosine kinase inhibitors.

Advances in management of hormone sensitive prostate cancer

Alok Gupta

Advances in management of castration resistant prostate cancer

Alok Gupta

Given this patient's advanced age and comorbidities, I would recommend abiraterone acetate as the second line treatment option post enzalutamide progression. Abiraterone has shown survival benefit with good tolerability in older patients with comorbidities in the COU-AA-301 trial. Cabazitaxel could be considered but may have higher toxicity risks in this patient. Close monitoring would be needed.

Mmc1 2 The Lancet - Supplementary appendix 10/15/2014

John Redaelli

This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Schwartz SD, Regillo CD, Lam BL, et al. Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt’s macular dystrophy: follow-up of two open-label phase 1/2 studies. Lancet 2014; published online Oct 15. http://dx.doi.org/10.1016/S0140-6736(14)61376-3.

Renal Cell Carcinoma A New Standard Of Care

fondas vakalis

This document summarizes the current standard of care for renal cell carcinoma (RCC), focusing on targeted therapies such as anti-angiogenesis agents. It reviews the biology and risk factors for RCC, the clinical efficacy and safety profiles of drugs like sorafenib and sunitinib, and phase III trial results demonstrating improved progression-free and overall survival compared to interferon-alpha. It concludes that anti-angiogenic therapies such as sorafenib, sunitinib, and temsirolimus have become the new standard first-line treatment for metastatic RCC based on superior clinical outcomes over existing immunotherapy options.

Gene therapy for NKTI Feb2013

David Dy

Gene therapy involves using genes to treat disease, such as cancer. It works by inserting a functional gene into a patient's cells to fight the disease. For cancer treatment, genes are inserted using an engineered adenovirus vector. One application is inserting the p53 tumor suppressor gene, which causes cancer cells to self-destruct. The document describes p53 gene therapy being administered directly into tumors or through injection for several cancer patients. Many showed tumor shrinkage or complete remission with only mild side effects like fever. Gene therapy is a promising treatment when combined with conventional therapies.

Farnesoid x receptor (fxr) and intestinal mucosa - Stefano Fiorucci

Attività scientifica

MCC 2011 - Slide 29

European School of Oncology

This document summarizes key points from a lecture on chemotherapy for advanced colorectal cancer. It discusses various chemotherapy regimens including monotherapy, doublets, and triplets. It also reviews data on adding biological therapies like bevacizumab and cetuximab to treatment. Finally, it presents findings on the predictive marker TOPO1 and plans for the FOCUS-3 trial to further evaluate biomarkers.

G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...

European School of Oncology

The document discusses renal cancer (kidney cancer) and advances in its treatment. It describes several targeted drugs that have improved outcomes for metastatic renal cell carcinoma (mRCC) compared to previous immunotherapy options. Drugs include tyrosine kinase inhibitors like sunitinib, sorafenib, pazopanib and axitinib as well as the mTOR inhibitor temsirolimus. Clinical trials have established these as standard first and second line options depending on a patient's risk level and prior treatment history. Ongoing research focuses on optimizing treatment sequencing and identifying biomarkers to guide more personalized therapy selection.

Bc endocrine resistance_2014_a

Mauricio Lema

The document discusses various strategies for overcoming resistance to endocrine therapy in advanced breast cancer, including targeting downstream signaling pathways like PI3K/Akt/mTOR that are often aberrantly activated in endocrine resistant disease. It reviews clinical trials demonstrating improved progression-free survival when adding drugs like everolimus or CDK4/6 inhibitors to hormonal therapy. The goal is to inhibit compensatory survival pathways that become relied upon by cancer cells to drive continued growth in the face of endocrine therapy.

Romito celiachia 19 dicembre 2012cmid

Bruno celiachia 19 dicembre 2012cmid

Similar to Alpa Mirella Torino 13° Convegno Patologia Immune E Malattie Orfane 21 23 Gennaio 2010 [Modalità Compati

presentation-presentation-biomarkers-arthur-burghes_en.pdf

MuhammadTanveer231769

Dr. Goy MCL

John Theurer Cancer Center at Hackensack University Medical Center

Kappos fingolimod moa-clin_results_vfinal_buenosaires1a

rubenroa

Martin duddy, drugs on the horizon

MS Trust

Estado actual de terapia sistémica en cáncer renal metastásico

Mauricio Lema

Salvage Chemotherapy for Head and Neck Cancer 2021-07 (New).ppt

SuYuChieh1

Incyte INCB39110 study results

innovaderm

$MCO 2011 - Slide 4 - K. Fizazi - Castration-refractory prostate cancer$ $MCO 2011 - Slide 4 - K. Fizazi - Castration-refractory prostate cancer$

MCO 2011 - Slide 4 - K. Fizazi - Castration-refractory prostate cancer

European School of Oncology

Cáncer páncreas 2017

UACH, Valdivia

Dr Alessandro Perra , Guna S,p.a.Italy

Investnet

Nets 2008 Carlos F Pinto

Carlos Frederico Pinto

Advances in management of hormone sensitive prostate cancer

Alok Gupta

Advances in management of castration resistant prostate cancer

Alok Gupta

Mmc1 2 The Lancet - Supplementary appendix 10/15/2014

John Redaelli

Renal Cell Carcinoma A New Standard Of Care

fondas vakalis

Gene therapy for NKTI Feb2013

David Dy

Farnesoid x receptor (fxr) and intestinal mucosa - Stefano Fiorucci

Attività scientifica

MCC 2011 - Slide 29

European School of Oncology

G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...

European School of Oncology

Bc endocrine resistance_2014_a

Mauricio Lema

Similar to Alpa Mirella Torino 13° Convegno Patologia Immune E Malattie Orfane 21 23 Gennaio 2010 [Modalità Compati (20)

presentation-presentation-biomarkers-arthur-burghes_en.pdf

Dr. Goy MCL

Kappos fingolimod moa-clin_results_vfinal_buenosaires1a

Martin duddy, drugs on the horizon

Estado actual de terapia sistémica en cáncer renal metastásico

Salvage Chemotherapy for Head and Neck Cancer 2021-07 (New).ppt

Incyte INCB39110 study results

$MCO 2011 - Slide 4 - K. Fizazi - Castration-refractory prostate cancer$ $MCO 2011 - Slide 4 - K. Fizazi - Castration-refractory prostate cancer$

MCO 2011 - Slide 4 - K. Fizazi - Castration-refractory prostate cancer

Cáncer páncreas 2017

Dr Alessandro Perra , Guna S,p.a.Italy

Nets 2008 Carlos F Pinto

Advances in management of hormone sensitive prostate cancer

Advances in management of castration resistant prostate cancer

Mmc1 2 The Lancet - Supplementary appendix 10/15/2014

Renal Cell Carcinoma A New Standard Of Care

Gene therapy for NKTI Feb2013

Farnesoid x receptor (fxr) and intestinal mucosa - Stefano Fiorucci

MCC 2011 - Slide 29

G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...

Bc endocrine resistance_2014_a

More from cmid

Romito celiachia 19 dicembre 2012cmid

Bruno celiachia 19 dicembre 2012cmid

Marangella celiachia 19 dicembre 2012cmid

Stella le urgenze in ematologia 21 maggio 2011cmid

Cattaneo le urgenze in ematologia 21 maggio 2011

cmid

This document discusses antiplatelet drugs used to prevent blood clots, including aspirin, clopidogrel, prasugrel, ticagrelor, cangrelor, and elinogrel. It summarizes the mechanisms of action, metabolism, efficacy, and safety profiles of these drugs. Resistance or variable response to certain antiplatelet drugs is also addressed. The ideal properties of an antithrombotic agent are outlined. Later generation drugs like prasugrel, ticagrelor, and cangrelor demonstrate more consistent platelet inhibition compared to clopidogrel. However, some such as ticagrelor and elinogrel are associated with higher rates of dyspnea.

Stella le urgenze in ematologia 21 maggio 2011cmid

Albani le urgenze in ematologia 21 maggio 2011cmid

Viora le urgenze in ematologia 21 maggio 2011cmid

Prisco le urgenze in ematologia 21 maggio 2011cmid

Milan le urgenze in ematologia 21maggio 2011cmid

Gugliemotti le urgenze in ematologia 21 maggio 2011cmid

Guglielmotti le urgenze in ematologia 21 maggio 2011cmid

Donvito le urgenze in ematologia 21 maggio 2011cmid

Bazzan guglielmotti le urgenze in ematologia_21 maggio 2011cmid

Albani_le urgenze in ematologia 21 maggio 2011cmid

Linfedema torino 4 e 5 farina giovanni [modalità compatibilità]cmid

Linfedema torino 4 e 5 marzo cazzoli stefania [modalità compatibilità]cmid

Linfedema torino 4 e 5 marzo de filippo guidocmid

Linfedema torino 4 e 5 marzo ditri luciano [modalità compatibilità]cmid

Linfedema torino 4 e 5 marzo gaal palma [modalità compatibilità]cmid

More from cmid (20)

Romito celiachia 19 dicembre 2012

Bruno celiachia 19 dicembre 2012

Marangella celiachia 19 dicembre 2012

Stella le urgenze in ematologia 21 maggio 2011

Cattaneo le urgenze in ematologia 21 maggio 2011

Stella le urgenze in ematologia 21 maggio 2011

Albani le urgenze in ematologia 21 maggio 2011

Viora le urgenze in ematologia 21 maggio 2011

Prisco le urgenze in ematologia 21 maggio 2011

Milan le urgenze in ematologia 21maggio 2011

Gugliemotti le urgenze in ematologia 21 maggio 2011

Guglielmotti le urgenze in ematologia 21 maggio 2011

Donvito le urgenze in ematologia 21 maggio 2011

Bazzan guglielmotti le urgenze in ematologia_21 maggio 2011

Albani_le urgenze in ematologia 21 maggio 2011

Linfedema torino 4 e 5 farina giovanni [modalità compatibilità]

Linfedema torino 4 e 5 marzo cazzoli stefania [modalità compatibilità]

Linfedema torino 4 e 5 marzo de filippo guido

Linfedema torino 4 e 5 marzo ditri luciano [modalità compatibilità]

Linfedema torino 4 e 5 marzo gaal palma [modalità compatibilità]

Recently uploaded

Role of Mukta Pishti in the Management of Hyperthyroidism

Dr. Jyothirmai Paindla

Abortion PG Seminar Power point presentation

AksshayaRajanbabu

Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx

Dr. Rabia Inam Gandapore

Part II - Body Grief: Losing parts of ourselves and our identity before, duri...

bkling

8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx

Holistified Wellness

We’re talking about Vedic Meditation, a form of meditation that has been around for at least 5,000 years. Back then, the people who lived in the Indus Valley, now known as India and Pakistan, practised meditation as a fundamental part of daily life. This knowledge that has given us yoga and Ayurveda, was known as Veda, hence the name Vedic. And though there are some written records, the practice has been passed down verbally from generation to generation.

Top-Vitamin-Supplement-Brands-in-India List

SwisschemDerma

All info about Diabetes and how to control it.

Gokuldas Hospital

Cardiac Assessment for B.sc Nursing Student.pdf

shivalingatalekar1

Netter's Atlas of Human Anatomy 7.ed.pdf

BrissaOrtiz3

LOOPS in orthodontics t loop bull loop vertical loop mushroom loop stop loop

debosmitaasanyal1

Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx

Dr. Rabia Inam Gandapore

The Nervous and Chemical Regulation of Respiration

MedicoseAcademics

These lecture slides, by Dr Sidra Arshad, offer a simplified look into the mechanisms involved in the regulation of respiration: Learning objectives: 1. Describe the organisation of respiratory center 2. Describe the nervous control of inspiration and respiratory rhythm 3. Describe the functions of the dorsal and respiratory groups of neurons 4. Describe the influences of the Pneumotaxic and Apneustic centers 5. Explain the role of Hering-Breur inflation reflex in regulation of inspiration 6. Explain the role of central chemoreceptors in regulation of respiration 7. Explain the role of peripheral chemoreceptors in regulation of respiration 8. Explain the regulation of respiration during exercise 9. Integrate the respiratory regulatory mechanisms 10. Describe the Cheyne-Stokes breathing Study Resources: 1. Chapter 42, Guyton and Hall Textbook of Medical Physiology, 14th edition 2. Chapter 36, Ganong’s Review of Medical Physiology, 26th edition 3. Chapter 13, Human Physiology by Lauralee Sherwood, 9th edition

K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu

HongBiThi1

Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central

19various

CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf

rishi2789

Cell Therapy Expansion and Challenges in Autoimmune Disease

Health Advances

There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities. In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions. Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved. Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.

Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx

Dr. Rabia Inam Gandapore

OCT Training Course for clinical practice Part 1

KafrELShiekh University

Adhd Medication Shortage Uk - trinexpharmacy.com

reignlana06

The UK is currently facing a Adhd Medication Shortage Uk, which has left many patients and their families grappling with uncertainty and frustration. ADHD, or Attention Deficit Hyperactivity Disorder, is a chronic condition that requires consistent medication to manage effectively. This shortage has highlighted the critical role these medications play in the daily lives of those affected by ADHD. Contact : +1 (747) 209 – 3649 E-mail : sales@trinexpharmacy.com

Top Effective Soaps for Fungal Skin Infections in India

SwisschemDerma

Recently uploaded (20)

Role of Mukta Pishti in the Management of Hyperthyroidism

Abortion PG Seminar Power point presentation

Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx

Part II - Body Grief: Losing parts of ourselves and our identity before, duri...

8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx

Top-Vitamin-Supplement-Brands-in-India List

All info about Diabetes and how to control it.

Cardiac Assessment for B.sc Nursing Student.pdf

Netter's Atlas of Human Anatomy 7.ed.pdf

LOOPS in orthodontics t loop bull loop vertical loop mushroom loop stop loop

Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx

The Nervous and Chemical Regulation of Respiration

K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu

Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central

CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf

Cell Therapy Expansion and Challenges in Autoimmune Disease

Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx

OCT Training Course for clinical practice Part 1

Adhd Medication Shortage Uk - trinexpharmacy.com

Top Effective Soaps for Fungal Skin Infections in India

Alpa Mirella Torino 13° Convegno Patologia Immune E Malattie Orfane 21 23 Gennaio 2010 [Modalità Compati

1. 13° CONVEGNOPATOLOGIA IMMUNE E 13°CONVEGNO PATOLOGIA IMMUNE E MALATTIE ORFANE, Torino 21-23/01/10 21- FARMACI BIOLOGICI NELLE VASCULITI ESPERIENZA MONOCENTRICA CMID MIRELLA ALPA Dipartimento di Malattie Rare, Immunologiche, Ematologiche ed Immunoematologiche Centro di Ricerche di Immunopatologia e Documentazione su Malattie Rare (CMID) Struttura Complessa a Direzione Universitaria di Immunologia Clinica, Ospedale G. Bosco

2. CLINICAL FEATURES AND OUTCOME OF PSV PTS TREATED WITH ANTICD20 MoAb PATIENT, ACTIVE ORGAN URINARY HEMATURIA FAILING THERAPY CREATININE VAS SCALE DIAGNOSIS AGE/GENDER INVOLVEMENT PROTEINS 1/39/M MMF, MTX, SP, K, PNS, J , F, S, W 0.7 0.4 50 9 mPa IVIgG, PE C 2/67/F MMF, SP K, F, W 1.1 1.1 50 7 mPa I 3/63/M Oral CYC, SP K, J, W 2.4 1.3 40 7 mPa R 4/71/F Oral CYC, SP PNS, J, F 0.9 0.5 0 6 mPa R 5/69/M MMF, SP K, PNS, J, F, W 1.4 1.4 15 6 WG relapsing 6/62/F MMF, K, L, F,W, PNS, J, 2.1 2.2 20 9 WG I SP, IVIgG M, ent 7/60/M CYC, PNS, S, J, H ,W 1.2 0.3 0 9 CS R SP, IVIgG 8/35/M Steroid L, F, W, J, ent 0.9 0.1 0 8 CS C 9/50/M Steroid, Mtx, anti- PNS, W, J, ent 0.8 0.1 5 7 WG TNF R 10/49/F SP, CYC, AZA, CyA K, W, J, PNS, ent 1.1 3.4 5 8 WG R 11/68/F SP, Oral CYC, IVIgG, K, ent, CNS, L 2 0.9 10 9 WG PE R

3. PATIENTS AND PROTOCOL 11 PTS: 5 WOMEN, 6 MEN (5 WG, 4 MPA, 2 CS) PTS: WG, MPA, CS) WITH INVOLVEMENT OF KIDNEY #7 PNS #7 ENT #5 LUNG #3 RETROORBITAL OR SINUS GRANULOMATA #2 CNS #1 RITUXIMAB 375 mg/sm DAYS # 0, 7, 14, 21 plus 2 DOSES AT 1 AND 2 MTHS

6. 35 30 29 28 26 B-VAS 25 20 20 15 16 15 12 11 10 6 5 3 2 2 0 T0 T12 p<0.01 at 12 months

7. 20 18 18 16 14 13 VDI 12 10 9 8 8 7 6 6 6 4 4 4 3 2 2 1 0 0 0 T0 T12 p<0.01 at 12 months

Alpa Mirella Torino 13° Convegno Patologia Immune E Malattie Orfane 21 23 Gennaio 2010 [Modalità Compati

Recommended

Recommended

More Related Content

Similar to Alpa Mirella Torino 13° Convegno Patologia Immune E Malattie Orfane 21 23 Gennaio 2010 [Modalità Compati

Similar to Alpa Mirella Torino 13° Convegno Patologia Immune E Malattie Orfane 21 23 Gennaio 2010 [Modalità Compati (20)

More from cmid

More from cmid (20)

Recently uploaded

Recently uploaded (20)

Alpa Mirella Torino 13° Convegno Patologia Immune E Malattie Orfane 21 23 Gennaio 2010 [Modalità Compati